Compare Hyatt Hotels Corporation (H) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Neurocrine Biosciences Inc — how do they compare? Hyatt Hotels Corporation trades at $161.78 (market cap $15.02B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Hyatt Hotels Corporation and Neurocrine Biosciences Inc are close in size by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Neurocrine Biosciences Inc for 23 Days on average.
| H | NBIX | |
|---|---|---|
Market Cap | $15.02B | $14.36B |
Volume | 842,340 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $185.50 |
52-Week Low | $135.42 | $123.10 |
Typical Hold Time | 148 Days | 23 Days |
Enterprise Value | $18.93B | $14.37B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $161.75, up 2.93% with recent earnings beats driving momentum. The stock shows neutral technical signals with mixed moving averages and oscillators. Fundamentally, revenue grew to $7.1B in 2025 but net income turned negative at -$52M, while valuation metrics remain elevated with P/E at 196.83. Recent developments include strategic partnerships with Delta Air Lines and expansion of the Essentials portfolio.
Outlook remains cautiously optimistic with analyst consensus target of $197.77 (22% upside) but high valuation and negative cash flow trends pose risks. The company's growth initiatives and brand expansion provide opportunities, though investors should monitor debt levels and profitability recovery.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
